In 2019, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled almost $3.98 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2019-2029 forecast period, biosimilars of Aranesp / Nesp (darbepoetin alfa) and Mircera (methoxy polyethylene glycol-epoetin beta) are expected to enter the major markets, alongside currently available epoetin alfa biosimilars, further increasing the need for companies to set competitive pricing to either gain or maintain ESA patient shares. We present our ESA forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and country / region.

Table of contents

  • Biosimilars - Market Events And Forecast - Nephrology
    • Market Forecast in the Major Pharmaceutical Markets
      • Major-Market Forecast: Nephrology Biologics (ESAs)
      • Terminology
      • Overarching Forecast Assumptions
        • Overview of ESA Brands in Forecast
          • Biosimilar Entry Assumptions for ESAs
        • Overview of Biosimilar ESA Assumptions
        • Drug-Specific Forecast Assumptions
          • Epogen, Procrit, Eprex, Espo
            • Outlook for Epogen / Procrit / Espo
            • First Major-Market ESA Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Epogen Sales Forecast in the United States: 2019-2029
            • Espo Sales Forecast in Japan: 2019-2029
            • Procrit Sales Forecast in the United States: 2019-2029
            • Eprex Sales Forecast in the EU5: 2019-2029
          • Aranesp / Nesp
            • Outlook for Aranesp / Nesp
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Aranesp Sales Forecast in the United States: 2019-2029
            • Aranesp Sales Forecast in the EU5: 2019-2029
            • Nesp Sales Forecast in Japan: 2019-2029
          • Mircera
            • Outlook for Mircera
            • First Major-Market Biosimilar Entrants
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Mircera Sales Forecast in the United States: 2019-2029
            • Mircera Sales Forecast in the EU5: 2019-2029
            • Mircera Sales Forecast in Japan: 2019-2029

      Author(s): Hamzah Aideed, M.Sc.; Yashu Malhotra

      Hamzah Aideed, M.Sc., is a principal analyst on the Biosimilars team at DRG, part of Clarivate. He conducts primary and secondary market research to provide in-depth analysis and insight into the biopharmaceutical industry. Prior to joining DRG, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.

      Yashu Malhotra, M.Sc., is an associate analyst on the Biosimilars and Onkos teams at DRG, part of Clarivate. Prior to joining DRG, she was a senior analyst in the life sciences at Course5 Intelligence. She also worked in competitive intelligence at WNS Global Services. Ms. Malhotra earned her master’s degree in pharmacy (quality assurance) from India’s Delhi Institute of Pharmaceutical Sciences and Research.